All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
| Status | Trial ID | Title | Completion date | Category |
|---|---|---|---|---|
| Listed as ongoing, but also has a completion date and reported results | 2005-005697-71 | Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method (rAHFPFM): A Phase 3/4, prospective, controlled, randomized, multi-center Study to compare the efficacy and safety of continous infusi... | 2015-12-09 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2010-022726-33 | BAX 326 (factor IX recombinante): Estudio de continuación sobre la evaluación de seguridad, inmunogenicidad y eficacia hemostática en pacientes tratados previamente portadores de hemofilia B grave (ni... | 2017-06-29 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2012-003221-19 | BAX 930 (rADAMTS13) | 2016-02-22 | bad-data |
| Reported results | 2013-001359-11 | A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures | 2016-09-25 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2013-002236-24 | A Phase 3b Continuation study of the Safety and Efficacy of PEGylated | 2018-03-02 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-000742-30 | A phase 3 prospective, uncontrolled, multicenter study evaluating pharmacokinetics, efficacy, safety, and immunogenicity of BAX 855 (PEGylated full-length Recombinant FVIII) in previously treated pedi... | 2015-10-23 | bad-data |
| Listed as ongoing, but also has a completion date and reported results | 2014-003575-38 | A PHASE 3 PROSPECTIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF rVWF WITH OR WITHOUT ADVATE IN ELECTIVE SURGICAL PROCEDURES IN SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE | 2016-07-06 | bad-data |
| Listed as ongoing, but also has a completion date | 2014-005477-37 | Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with ... | 2018-08-05 | bad-data |
| Ongoing | 2014-005496-87 | A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), ... | not-yet-due | |
| Reported results | 2015-000896-28 | A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination with 5-FU/Leucovorin or Panitumumab versus Standard of Care in Subjects with Metastatic... | 2017-02-18 | due-trials |
| Listed as ongoing, but also has a completion date and reported results | 2015-001751-76 | A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects with Moderate to Severe Chronic Plaque... | 2017-04-04 | bad-data |
| Other | 2015-002136-40 | Phase 3, prospective, multi-center, open label study to investigate safety, immunogenicity, and hemostatic efficacy of PEGylated Factor VIII (BAX 855) in previously untreated patients (PUPs) < 6 years... | not-yet-due | |
| Completed, but no date | 2015-002345-64 | A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion with Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects with Immunoglobulin A Nephropathy (IgAN) | bad-data | |
| Completed, but no date, and reported results | 2015-003492-29 | A Phase 1/2a, Open-Label, Parallel, Two-Arm, Dose-Escalation | bad-data | |
| Other | 2015-005521-39 | A Phase 3, Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects with Congenital Hemophilia A with Factor VIII ... | not-yet-due | |
| Ongoing | 2016-000374-37 | Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuro... | not-yet-due | |
| Ongoing | 2016-001477-33 | A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF with or without ADVATE in the Treatment and Control of Bleeding... | not-yet-due | |
| Ongoing | 2016-001478-14 | A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL | not-yet-due | |
| Other | 2016-003438-26 | Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects with Primary Immunodeficiency Diseases | not-yet-due | |
| Other | 2017-000858-18 | A phase 3, prospective, randomized, controlled, open-label, multicenter, 2-period crossover study with a single arm continuation evaluating the safety and efficacy of BAX 930 (rADAMTS13) in the prophy... | not-yet-due |